| Authors: |
Jerby-Arnon L; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Shah P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cuoco MS; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rodman C; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Su MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA., Melms JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leeson R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA., Kanodia A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA., Mei S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Lin JR; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Wang S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Rabasha B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Zhang G; Molecular & Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA., Margolais C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ashenberg O; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boland GM; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Frederick DT; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Miao B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Moll T; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Herlyn M; Molecular & Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA., Jenkins RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Thummalapalli R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kowalczyk MS; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Celsius Therapeutics, Cambridge, MA, USA., Cañadas I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Schilling B; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium, Essen, Germany; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany., Cartwright ANR; Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Luoma AM; Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Malu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shalek AK; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Tirosh I; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sorger PK; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Wucherpfennig K; Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Schadendorf D; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium, Essen, Germany., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA., Rotem A; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA., Rozenblatt-Rosen O; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Garraway LA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA; Ludwig Center for Cancer Research at Harvard, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Yoon CH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Department of Surgical Oncology, Boston, MA, USA., Izar B; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Cancer Precision Medicine of Dana-Farber Cancer Institute, Boston, MA, USA; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA; Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Ludwig Center for Cancer Research at Harvard, Boston, MA, USA. Electronic address: benjamin_izar@dfci.harvard.edu., Regev A; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Ludwig Center for Cancer Research at MIT, Boston, MA, USA; Massachusetts Institute of Technology, Department of Biology, Cambridge, MA, USA. |
